Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)

Next Previous
Trial Profile

A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cladribine (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms MAGNIFY; MAGNIFY-MS
  • Sponsors Merck KGaA

    • Most Recent Events

    • 02 Mar 2024 Results investigating cognitive performance in patients with highly active relapsing MS, presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024
    • 13 Oct 2023 Results of post-hoc analysis assessing the changes in lymphocyte subsetcounts and their association with MRI outcomes in pwMS receiv-ing cladribine tablets treatment for highly active relapsing MS, presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis.
    • 13 Oct 2023 Results (n=211) of an exploratory post-hoc analysis assessing associations between normalized sNfL Z-score changes based on control cohorts and treatment outcomes defined by MRI presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top